Cas:7313-22-6 N,N,N’,N’-tetramethylpropanediamide manufacturer & supplier

We serve Chemical Name:N,N,N’,N’-tetramethylpropanediamide CAS:7313-22-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N,N,N',N'-tetramethylpropanediamide

Chemical Name:N,N,N’,N’-tetramethylpropanediamide
CAS.NO:7313-22-6
Synonyms:N,N,N’,N’-Tetramethylmalonsaeurediamid;N,N,N’,N’-tetrametilmalonammide;T1891;N,N,N’,N’-Tetramethylmalonamid;N,N,N’,N’-tetramethyl-malonamide
Molecular Formula:C7H14N2O2
Molecular Weight:158.19800
HS Code:2924199090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:160ºC / 10mmHg
Density:1.1 g/cm3
Index of Refraction:1.462
PSA:40.62000
Exact Mass:158.10600
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N,N,N’,N’-Tetramethylmalonsaeurediamid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N,N’,N’-tetramethyl-malonamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,T1891 Use and application,N,N,N’,N’-Tetramethylmalonsaeurediamid technical grade,usp/ep/jp grade.


Related News: CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up. trichloro(2,3-dichlorobutyl)silane manufacturers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. 2-(dichloromethylsilyl)propanenitrile suppliers Except current data is insufficient to determine its benefit in patients who are negative for anti-AChR antibodies. Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxycarbonylimino-1,3-phenylene(phenylphosphinylidene)-1,3-phenyleneiminocarbonyl] vendor & factory GSK picked McNamara after six months of “extensive search and selection process,” GSK said in its announcement Thursday. It ran the quest with help from two headhunters and evaluated “several external and internal candidates,” it said.,CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up.